Open AccessJournal Article
Montelukast as a treatment modality for eosinophilic gastroenteritis.
Reads0
Chats0
TLDR
In this paper, a 38-year old man with steroid-dependent eosinophilic Gastroenteritis (EG) was successfully treated with montelukast, a leukotriene receptor antagonist.Abstract:
Eosinophilic Gastroenteritis (EG) is a rare condition, caused by eosinophilic inflammatory infiltrates in the gastrointestinal tract. It is usually treated successfully with systemic glucocorticoids. Because of frequent relapses, however, there is need for alternatives. We describe a 38-year old man with steroid-dependent EG, who was successfully treated with montelukast, a leukotriene receptor antagonist. It inhibits leukotriene D4, an important cytokine in the inflammatory cascade. Although montelukast could not replace steroid therapy, it acted as a steroid sparing agent in our patient. Review of the literature shows that montelukast is efficient in the treatment of EG in a part of the patients. The low cost, the low number of side effects and its efficiency make it an interesting alternative in relapsing or steroid dependent EG. There is need for multicentric studies regarding the treatment of EG.read more
Citations
More filters
Journal ArticleDOI
Cysteinyl leukotriene receptor-1 antagonists as modulators of innate immune cell function
Annette J. Theron,Helen C. Steel,Gregory Ronald Tintinger,Cornelia M. Gravett,Ronald Anderson,Charles Feldman +5 more
TL;DR: A review of selective cysLT receptor-1 (cysLTR1) antagonists, specifically montelukast, pranlukast, and zafirlukast can be found in this paper.
Journal ArticleDOI
Eosinophilic gastroenteritis: an update
Alfredo J. Lucendo,Ángel Arias +1 more
TL;DR: The natural history of EGE includes three different evolutionary patterns, since patients may suffer a single outbreak, a recurrent course or even chronic disease.
Journal ArticleDOI
Eosinophilic gastroenteritis: Approach to diagnosis and management.
Antoine Abou Rached,Weam El Hajj +1 more
TL;DR: An algorithm is designed and applied to clarify the steps to follow for diagnosis of EGE in clinical practice and to summary of various therapeutic modalities for EGE management according to disease severity upon presentation.
Journal ArticleDOI
Eosinophilic gastrointestinal diseases beyond eosinophilic esophagitis
TL;DR: With the seeming increase in all types of EGIDs, phenotypic descriptions are emerging that will likely promote better understanding of the pathogenesis and identification of novel therapeutic targets.
Journal ArticleDOI
Eosinophilic gastrointestinal diseases – Pathogenesis, diagnosis, and treatment
TL;DR: Three useful options for treating EoE patients are acid inhibitors, swallowed topical corticosteroids, and an elimination diet, while systemic administration of glucocorticoids is the standard treatment of EGE, though information is limited.
References
More filters
Journal ArticleDOI
Eosinophilic gastroenteritis: a clinicopathological study of patients with disease of the mucosa, muscle layer, and subserosal tissues.
TL;DR: Eos inophilic gastroenteritis should be considered in the differential diagnosis of unexplained gastrointestinal symptoms even in the absence of peripheral eosinophilia, according to the clinicopathological spectrum.
Journal ArticleDOI
Anti–IL-5 (mepolizumab) therapy for eosinophilic esophagitis
Miguel Stein,Margaret H. Collins,Joyce Villanueva,Jonathan P. Kushner,Philip E. Putnam,Bridget K. Buckmeier,Alexandra H. Filipovich,Amal Assa'ad,Marc E. Rothenberg +8 more
TL;DR: Anti-IL-5 therapy is associated with marked decreases in peripheral blood and esophageal eosinophilia in patients with EE and improved clinical outcomes, and is a promising therapeutic intervention for EE.
Journal ArticleDOI
Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes.
Jennifer K. Garrett,Sean C. Jameson,Blythe Thomson,Margaret H. Collins,Lynne E. Wagoner,Debbie K Freese,Lisa A. Beck,Joshua A. Boyce,Alexandra H. Filipovich,Joyce Villanueva,Steven A. Sutton,Amal Assa'ad,Marc E. Rothenberg +12 more
TL;DR: It is suggested that anti-IL-5 is safe, effective in lowering eosinophil levels, and has potential glucocorticoid-sparing effects in patients with a variety of hyper-eOSinophilic syndromes.
Journal ArticleDOI
Eosinophilic gastroenteritis: Clinical experience with 15 patients
TL;DR: Eosinophilic gastroenteritis is a rare condition of unclear etiology characterized by relapses and remissions and short courses of corticosteroids are the mainstay of treatment, although some patients with relapsing disease require long-term low-dose steroids.
Journal ArticleDOI
Anti-IgE treatment of eosinophil-associated gastrointestinal disorders
Shabnam Foroughi,Barbara Foster,Nayoung Kim,Leigh B. Bernardino,Linda M. Scott,Robert G. Hamilton,Dean D. Metcalfe,Peter J. Mannon,Calman Prussin +8 more
TL;DR: It is demonstrated that IgE-mediated processes contribute to the generation of eosinophilic inflammation in EGIDs and suggest that anti-IgE therapy might be effective in these disorders.